SCHEMBL2955244

SCHEMBL2955244

Oc1n[nH]c2cc(Cl)ccc12

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP2K4 P45985 3/20 0.55
GSK3B P49841 2/20 0.48
TRPA1 O75762 1/20 0.46
PDPK1 O15530 1/20 0.42
HSP90AB1 P08238 1/20 0.42
DAO P14920 1/20 0.41
NOS1 P29475 1/20 0.41
DYRK1A Q13627 1/20 0.41
FGFR1 P11362 1/20 0.41
FGFR2 P21802 1/20 0.41
FGFR3 P22607 1/20 0.41
ALDH1A1 P00352 1/20 0.40
CHEK1 O14757 1/20 0.40
ESR1 P03372 1/20 0.40
GRIN2D O15399 1/20 0.39
GRIN3B O60391 1/20 0.39
GRIN1 Q05586 1/20 0.39
GRIN2A Q12879 1/20 0.39
GRIN2B Q13224 1/20 0.39
GRIN2C Q14957 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11010462 0.84 FADS1 (0.49) MAP2K4NOS1CHEK1GRIN2DGRIN3B
SCHEMBL3593032 0.79 MAP2K4 (0.50) MAP2K4GSK3BTRPA1DAONOS1
SCHEMBL14738828 0.79 MAP2K4 (0.63) MAP2K4GSK3BTRPA1PDPK1HSP90AB1
SCHEMBL4502873 0.78 PDPK1 (0.60) MAP2K4GSK3BTRPA1PDPK1CHEK1
SCHEMBL1573990 0.78 MAP2K4 (0.58) MAP2K4PDPK1HSP90AB1DAOFGFR1
SCHEMBL4032441 0.77 PDPK1 (0.75) MAP2K4PDPK1HSP90AB1FGFR1FGFR2
SCHEMBL445902 0.76 FGFR1 (0.50) MAP2K4GSK3BPDPK1HSP90AB1FGFR1
SCHEMBL2302544 0.76 PDPK1 (0.63) MAP2K4GSK3BPDPK1HSP90AB1NOS1
SCHEMBL30016013 0.76 PDPK1 (0.63) MAP2K4GSK3BPDPK1HSP90AB1NOS1
SCHEMBL15529807 0.76 GSK3B (0.48) MAP2K4GSK3BTRPA1PDPK1DAO

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1937648-B1 DIACYL INDAZOL DERIVATIVES AS LIPASE AND PHOSPHOLIPASE INHIBITORS SANOFI SA (FR) 2014-11-26 EP disclosed
US-8357698-B2 Diacyl indazole derivatives as lipase and phospholipase inhibitors SANOFI (FR) 2013-01-22 US disclosed
US-20100286133-A1 Diacyl indazole derivatives as lipase and phospholipase inhibitors SANOFI-AVENTIS (FR) 2010-11-11 US disclosed
US-7772268-B2 inhibitors of hormone-sensitive lipase and/or endothelial lipase; for treatment of diabetes mellitus, dyslipidemia and atherosclerotic disorders SANOFI-AVENTIS (FR) 2010-08-10 US disclosed
US-7521480-B2 Aryl ureido benzoic acid derivatives and their use NEUROSEARCH (DK) 2009-04-21 US disclosed
US-20080287448-A1 Diacyl indazole derivatives as lipase and phospholipase inhibitors SANOFI-AVENTIS (FR) 2008-11-20 US disclosed
CN-101282939-A Diacyl indazole derivatives as lipase and phospholipase inhibitors SANOFI AVENTIS (FR) 2008-10-08 CN disclosed
EP-1937648-A1 DIACYL INDAZOL DERIVATIVES AS LIPASE AND PHOSPHOLIPASE INHIBITORS sanofi-aventis (FR) 2008-07-02 EP disclosed
WO-2007042178-A1 DIACYL INDAZOL DERIVATIVES AS LIPASE AND PHOSPHOLIPASE INHIBITORS SANOFI-AVENTIS (DE) 2007-04-19 WO disclosed
US-20060069255-A1 Novel aryl ureido benzoic acid derivatives and their use NEUROSEARCH (DK) 2006-03-30 US disclosed
CN-1714076-A Novel aryl ureido benzoic acid derivatives and their use NEUROSEARCH AS (DK) 2005-12-28 CN disclosed
EP-1565429-A2 ARYL UREIDO DERIVATIVES AND THEIR MEDICAL USE NEUROSEARCH A/S (DK) 2005-08-24 EP disclosed
WO-2004046090-A2 ARYL UREIDO DERIVATIVES AND THEIR MEDICAL USE NEUROSEARCH A/S (DK) 2004-06-03 WO disclosed
US-4537966-A 1-(Aminobenzoyl)-1H-indazol-3-ols PENNWALT CORPORATION (US) 1985-08-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080287448-A1 Diacyl indazole derivatives as lipase and phospholipase inhibitors PNLIP, DAGLA, MGLL MAP2K4 3435/4885GSK3B 1568/4885TRPA1 2152/4885
US-20060069255-A1 Novel aryl ureido benzoic acid derivatives and their use GABRA5, GRIK5, GRM5 MAP2K4 3894/4885GSK3B 4769/4885TRPA1 659/4885
US-20100286133-A1 Diacyl indazole derivatives as lipase and phospholipase inhibitors PNLIP, DAGLA, MGLL MAP2K4 3435/4885GSK3B 1568/4885TRPA1 2152/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.